Search

Your search keyword '"Kikuchi Akio"' showing total 148 results
Start Over Author "Kikuchi Akio" Search Limiters Full Text
148 results on '"Kikuchi Akio"'

1. Extraction time for soybean isoflavone determination

Author

Carrão-Panizzi Mercedes C., Favoni Silvana Pedroso de Goés, and Kikuchi Akio

Subjects
Soybeans, isoflavones, glucosides, aglucones, extraction, ethanol, HPLC, Biotechnology, TP248.13-248.65
Abstract

Studies were carried out on the optimization of the extraction procedures for isoflavones determination in soybean by HPLC. Isoflavones were extracted from 100 mg samples of full fat soybean flour "Kinako" (milled toasted grains). Recovery of average total isoflavones was higher when extraction was performed with agitation(217.2 mg/100g), than without agitation(191.0 mg/100g). Isoflavone extraction without agitation for 1,4, 20 and 24 hours, were equally efficient for total and individual compounds. These results suggested that an efficient isoflavone recovery could be achieved with extraction for one hour with agitation.

Published
2002

2. Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy

Author

Konno Masatoshi, Hasegawa Takafumi, Baba Toru, Miura Emiko, Sugeno Naoto, Kikuchi Akio, Fiesel Fabienne C, Sasaki Tsutomu, Aoki Masashi, Itoyama Yasuto, and Takeda Atsushi

Subjects
α-synuclein, Neuron, Oligodendroglia, Transmission, Inclusions, Endocytosis, Dynamin, Sertraline, Parkinson’s disease, Multiple system atrophy, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract Background The intracellular deposition of misfolded proteins is a common neuropathological hallmark of most neurodegenerative disorders. Increasing evidence suggests that these pathogenic proteins may spread to neighboring cells and induce the propagation of neurodegeneration. Results In this study, we have demonstrated that α-synuclein (αSYN), a major constituent of intracellular inclusions in synucleinopathies, was taken up by neuronal and oligodendroglial cells in both a time- and concentration-dependent manner. Once incorporated, the extracellular αSYN was immediately assembled into high-molecular-weight oligomers and subsequently formed cytoplasmic inclusion bodies. Furthermore, αSYN uptake by neurons and cells of the oligodendroglial lineage was markedly decreased by the genetic suppression and pharmacological inhibition of the dynamin GTPases, suggesting the involvement of the endocytic pathway in this process. Conclusions Our findings shed light on the mode of αSYN uptake by neuronal and oligodendroglial cells and identify therapeutic strategies aimed at reducing the propagation of protein misfolding.

Published
2012
Full Text
View/download PDF

3. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Author

Höglinger, Günter U, Litvan, Irene, Mendonca, Nuno, Wang, Deli, Zheng, Hui, Rendenbach-Mueller, Beatrice, Lon, Hoi-Kei, Jin, Ziyi, Fisseha, Nahome, Budur, Kumar, Gold, Michael, Ryman, Davis, Florian, Hana, Investigators, Arise, Ahmed, Anwar, Aiba, Ikuko, Albanese, Alberto, Bertram, Kelly, Bordelon, Yvette, Bower, James, Brosch, Jared, Claassen, Daniel, Colosimo, Carlo, Corvol, Jean-Christophe, Cudia, Paola, Daniele, Antonio, Defebvre, Luc, Driver-Dunckley, Erika, Duquette, Antoine, Eleopra, Roberto, Eusebio, Alexandre, Fung, Victor, Geldmacher, David, Golbe, Lawrence, Grandas, Francisco, Hall, Deborah, Hatano, Taku, Honig, Lawrence, Hui, Jennifer, Kerwin, Diana, Kikuchi, Akio, Kimber, Thomas, Kimura, Takashi, Kumar, Rajeev, Ljubenkov, Peter, Lorenzl, Stefan, Ludolph, Albert, Mari, Zoltan, McFarland, Nikolaus, Meissner, Wassilios, Rivera, Pablo Mir, Mochizuki, Hidek, Morgan, John, Munhoz, Renato, Nishikawa, Noriko, O`Sullivan, John, Oeda, Tomoko, Oizumi, Hideki, Onodera, Osamu, Ory-Magne, Fabienne, Peckham, Elizabeth, Postuma, Ronald, Quattrone, Aldo, Quinn, Joseph, Ruggieri, Stefano, Sarna, Justyna, Schulz, Paul E, Slevin, John, Tagliati, Michele, Wile, Daryl, Wszolek, Zbigniew, Xie, Tao, and Zesiewicz, Theresa

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Brain Disorders, Clinical Research, Clinical Trials and Supportive Activities, Patient Safety, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Neurological, Administration, Intravenous, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Female, Humans, Male, Middle Aged, Supranuclear Palsy, Progressive, Treatment Outcome, tau Proteins, Arise Investigators, Neurology & Neurosurgery, Clinical sciences
Abstract

BackgroundProgressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy.MethodsWe did a phase 2, multicentre, randomised, placebo-controlled, double-blind study at 66 hospitals and clinics in Australia, Canada, France, Germany, Italy, Japan, Spain, and the USA. Participants (aged ≥40 years) diagnosed with possible or probable progressive supranuclear palsy who were symptomatic for less than 5 years, had a reliable study partner, and were able to walk five steps with minimal assistance, were randomly assigned (1:1:1) by interactive response technology to tilavonemab 2000 mg, tilavonemab 4000 mg, or matching placebo administered intravenously on days 1, 15, and 29, then every 28 days through to the end of the 52-week treatment period. Randomisation was done by the randomisation specialist of the study sponsor, who did not otherwise participate in the study. The sponsor, investigators, and participants were unaware of treatment allocations. The primary endpoint was the change from baseline to week 52 in the Progressive Supranuclear Palsy Rating Scale (PSPRS) total score in the intention-to-treat population. Adverse events were monitored in participants who received at least one dose of study drug. Prespecified interim futility criteria were based on a model-based effect size of 0 or lower when 60 participants had completed the 52-week treatment period and 0·12 or lower when 120 participants had completed the 52-week treatment period. This study is registered at ClinicalTrials.gov, number NCT02985879.FindingsBetween Dec 12, 2016, and Dec 31, 2018, 466 participants were screened, 378 were randomised. The study was terminated on July 3, 2019, after prespecified futility criteria were met at the second interim analysis. A total of 377 participants received at least one dose of study drug and were included in the efficacy and safety analyses (2000 mg, n=126; 4000 mg, n=125; placebo, n=126). Least squares mean change from baseline to week 52 in PSPRS was similar in all groups (between-group difference vs placebo: 2000 mg, 0·0 [95% CI -2·6 to 2·6], effect size 0·000, p>0·99; 4000 mg, 1·0 [-1·6 to 3·6], -0·105, p=0·46). Most participants reported at least one adverse event (2000 mg, 111 [88%]; 4000 mg, 111 [89%]; placebo, 108 [86%]). Fall was the most common adverse event (2000 mg, 42 [33%]; 4000 mg, 54 [43%]; placebo, 49 [39%]). Proportions of patients with serious adverse events were similar among groups (2000 mg, 29 [23%]; 4000 mg, 34 [27%]; placebo, 33 [26%]). Fall was the most common treatment-emergent serious adverse event (2000 mg, five [4%]; 4000 mg, six [5%]; placebo, six [5%]). 26 deaths occurred during the study (2000 mg, nine [7%]; 4000 mg, nine [7%]; placebo, eight [6%]) but none was drug related.InterpretationA similar safety profile was seen in all treatment groups. No beneficial treatment effects were recorded. Although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear palsy.FundingAbbVie Inc.

Published
2021

5. Mirror writing and cortical hypometabolism in Parkinson’s disease

Author

Shinohara, Mayumi, primary, Yokoi, Kayoko, additional, Hirayama, Kazumi, additional, Kanno, Shigenori, additional, Hosokai, Yoshiyuki, additional, Nishio, Yoshiyuki, additional, Ishioka, Toshiyuki, additional, Otsuki, Mika, additional, Takeda, Atsushi, additional, Baba, Toru, additional, Aoki, Masashi, additional, Hasegawa, Takafumi, additional, Kikuchi, Akio, additional, Narita, Wataru, additional, Mori, Etsuro, additional, and Suzuki, Kyoko, additional

Published
2022
Full Text
View/download PDF

7. 18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies

Author

Ezura, Michinori, primary, Kikuchi, Akio, additional, Okamura, Nobuyuki, additional, Ishiki, Aiko, additional, Hasegawa, Takafumi, additional, Harada, Ryuichi, additional, Watanuki, Shoichi, additional, Funaki, Yoshihito, additional, Hiraoka, Kotaro, additional, Baba, Toru, additional, Sugeno, Naoto, additional, Yoshida, Shun, additional, Kobayashi, Junpei, additional, Kobayashi, Michiko, additional, Tano, Ohito, additional, Ishiyama, Shun, additional, Nakamura, Takaaki, additional, Nakashima, Ichiro, additional, Mugikura, Shunji, additional, Iwata, Ren, additional, Taki, Yasuyuki, additional, Furukawa, Katsutoshi, additional, Arai, Hiroyuki, additional, Furumoto, Shozo, additional, Tashiro, Manabu, additional, Yanai, Kazuhiko, additional, Kudo, Yukitsuka, additional, Takeda, Atsushi, additional, and Aoki, Masashi, additional

Published
2021
Full Text
View/download PDF

12. 18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging

Author

Harada, Ryuichi, primary, Hayakawa, Yoshimi, additional, Ezura, Michinori, additional, Lerdsirisuk, Pradith, additional, Du, Yiqing, additional, Ishikawa, Yoichi, additional, Iwata, Ren, additional, Shidahara, Miho, additional, Ishiki, Aiko, additional, Kikuchi, Akio, additional, Arai, Hiroyuki, additional, Kudo, Yukitsuka, additional, Yanai, Kazuhiko, additional, Furumoto, Shozo, additional, and Okamura, Nobuyuki, additional

Published
2020
Full Text
View/download PDF

15. In vivo visualization of α-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy

Author

Kikuchi, Akio, Takeda, Atsushi, Okamura, Nobuyuki, Tashiro, Manabu, Hasegawa, Takafumi, Furumoto, Shozo, Kobayashi, Michiko, Sugeno, Naoto, Baba, Toru, Miki, Yasuo, Mori, Fumiaki, Wakabayashi, Koichi, Funaki, Yoshihito, Iwata, Ren, Takahashi, Shoki, Fukuda, Hiroshi, Arai, Hiroyuki, Kudo, Yukitsuka, Yanai, Kazuhiko, and Itoyama, Yasuto

Published
2010
Full Text
View/download PDF

16. 18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies.

Author

Ezura, Michinori, Kikuchi, Akio, Okamura, Nobuyuki, Ishiki, Aiko, Hasegawa, Takafumi, Harada, Ryuichi, Watanuki, Shoichi, Funaki, Yoshihito, Hiraoka, Kotaro, Baba, Toru, Sugeno, Naoto, Yoshida, Shun, Kobayashi, Junpei, Kobayashi, Michiko, Tano, Ohito, Ishiyama, Shun, Nakamura, Takaaki, Nakashima, Ichiro, Mugikura, Shunji, and Iwata, Ren

Subjects
POSITRON emission tomography, PROGRESSIVE supranuclear palsy, FRONTAL lobe, TEMPORAL lobe, MONTREAL Cognitive Assessment
Abstract

Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer's disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters. Methods: 18F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke's Cognitive Examination–Revised, and Frontal Assessment Battery, Unified Parkinson's Disease Rating Scale Motor Score, and PSP Rating Scale. Results: 18F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. 18F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, 18F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional 18F-THK5351 retention was associated with the cognitive function in CBS and PSP. Conclusion: Measurement of the tau deposits and MAO-B density in the brain using 18F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

17. Transfer of the Rsv3 locus from ‘Harosoy’ for resistance to soybean mosaic virus strains C and D in Japan

Author

Kato, Shin, Takada, Yoshitake, Shimamura, Satoshi, Hirata, Kaori, Sayama, Takashi, Taguchi-Shiobara, Fumio, Ishimoto, Masao, Kikuchi, Akio, and Nishio, Takeshi

Subjects
Glycine max, soybean mosaic virus, SMV strains, Note, Rsv3, marker-assisted selection
Abstract

Resistance to soybean mosaic virus (SMV) is imperative for soybean (Glycine max (L.) Merr.) production in the Tohoku region. Molecular markers for SMV resistance were previously reported for U.S. SMV strains, but they cannot be applied because of the differences in strain classification between Japan and the U.S. A U.S. variety 'Harosoy' has been used mainly as a donor of resistance to SMV strains C and D in a Japanese breeding program, resulting in resistant varieties such as 'Fukuibuki.' Because 'Harosoy' harbors the Rsv3 gene conferring resistance to the virulent SMV strain groups, G5 through G7, it appears that the Rsv3 gene confers resistance to strains C and D. In this study, we introduced resistance to the two strains from 'Fukuibuki' into a leading variety 'Ohsuzu' by recurrent backcrossing with marker-assisted selection. All lines selected with markers near Rsv3 showed resistance to the strains, suggesting that the Rsv3 locus is responsible for the resistance. Three years of trials showed that one of the breeding lines, 'Tohoku 169,' was equivalent to 'Ohsuzu' with respect to agricultural characteristics such as seed size, maturity date, and seed yield, except for the SMV resistance.

Published
2016

21. Annual report on the effluent control of low level liquid waste in Nuclear Fuel Cycle Engineering Laboratories FY2015

Author

Nakano, Masanao, Fujita, Hiroki, Kono, Takahiko, Nagaoka, Mika, Inoue, Kazumi, Yoshii, Hideki, Otani, Kazunori, Hiyama, Yoshinori, Kikuchi, Masaaki, Sakauchi, Nobuyuki, Koakutsu, Shinji, Kikuchi, Akio, Asano, Naoki, Terada, Hideyuki, Ishiyama, Toru, Yamaguchi, Yuji, Shimizu, Harunori, Okada, Noriyuki, and Kaneta, Yoshiharu

Abstract

本報告書は、原子力規制関係法令を受けた「再処理施設保安規定」、「核燃料物質使用施設保安規定」、「放射線障害予防規程」、「放射線保安規則」及び「茨城県等との原子力施設周辺の安全確保及び環境保全に関する協定書」、「水質汚濁防止法」並びに「茨城県条例」に基づき、平成27年4月1日から平成28年3月31日までの期間に日本原子力研究開発機構核燃料サイクル工学研究所から環境へ放出した放射性排水の放出管理結果をとりまとめたものである。再処理施設、プルトニウム燃料開発施設をはじめとする各施設からの放射性液体廃棄物は、濃度及び放出量ともに保安規定及び協定書等に定められた基準値を十分に下回った。, Based on the regulations (the safety regulation of Tokai reprocessing plant, the safety regulation of nuclear fuel material usage facilities, the radiation safety rule, the regulation about prevention from radiation hazards due to radioisotopes, which are related with the nuclear regulatory acts, the local agreement concerning with safety and environment conservation around nuclear facilities, the water pollution control law, and bylaw of Ibaraki prefecture), the effluent control of liquid waste discharged from the Nuclear Fuel Cycle Engineering Laboratories of Japan Atomic Energy Agency has been performed. This report describes the effluent control results of the liquid waste in the fiscal year 2015. In this period, the concentrations and the quantities of the radioactivity in liquid waste discharged from the reprocessing plant, the plutonium fuel fabrication facilities, and the other nuclear fuel material usage facilities were much lower than the limits authorized by the above regulations.

Published
2017

23. Parkinson’s disease-linked DNAJC13 mutation aggravates alpha-synuclein-induced neurotoxicity through perturbation of endosomal trafficking

Author

Yoshida, Shun, primary, Hasegawa, Takafumi, additional, Suzuki, Mari, additional, Sugeno, Naoto, additional, Kobayashi, Junpei, additional, Ueyama, Morio, additional, Fukuda, Mitsunori, additional, Ido-Fujibayashi, Akemi, additional, Sekiguchi, Kiyotoshi, additional, Ezura, Michinori, additional, Kikuchi, Akio, additional, Baba, Toru, additional, Takeda, Atsushi, additional, Mochizuki, Hideki, additional, Nagai, Yoshitaka, additional, and Aoki, Masashi, additional

Published
2018
Full Text
View/download PDF

25. 平成27年度核燃料サイクル工学研究所放出管理業務報告書(排水)

Author

中野 政尚, Nakano, Masanao, 藤田 博喜, Fujita, Hiroki, 河野 恭彦, Kono, Takahiko, 永岡 美佳, Nagaoka, Mika, 井上 和美, Inoue, Kazumi, 吉井 秀樹, Yoshii, Hideki, 大谷 和義, Otani, Kazunori, 檜山 佳典, Hiyama, Yoshinori, 菊地 政昭, Kikuchi, Masaaki, 坂内 信行, Sakauchi, Nobuyuki, 小圷 真司, Koakutsu, Shinji, 菊池 明夫, Kikuchi, Akio, 浅野 直紀, Asano, Naoki, 寺田 秀行, Terada, Hideyuki, 石山 道, Ishiyama, Toru, 山口 祐二, Yamaguchi, Yuji, 清水 治憲, Shimizu, Harunori, 岡田 典之, Okada, Noriyuki, 金田 美治, Kaneta, Yoshiharu, 中野 政尚, Nakano, Masanao, 藤田 博喜, Fujita, Hiroki, 河野 恭彦, Kono, Takahiko, 永岡 美佳, Nagaoka, Mika, 井上 和美, Inoue, Kazumi, 吉井 秀樹, Yoshii, Hideki, 大谷 和義, Otani, Kazunori, 檜山 佳典, Hiyama, Yoshinori, 菊地 政昭, Kikuchi, Masaaki, 坂内 信行, Sakauchi, Nobuyuki, 小圷 真司, Koakutsu, Shinji, 菊池 明夫, Kikuchi, Akio, 浅野 直紀, Asano, Naoki, 寺田 秀行, Terada, Hideyuki, 石山 道, Ishiyama, Toru, 山口 祐二, Yamaguchi, Yuji, 清水 治憲, Shimizu, Harunori, 岡田 典之, Okada, Noriyuki, 金田 美治, and Kaneta, Yoshiharu

Abstract

本報告書は、原子力規制関係法令を受けた「再処理施設保安規定」、「核燃料物質使用施設保安規定」、「放射線障害予防規程」、「放射線保安規則」及び「茨城県等との原子力施設周辺の安全確保及び環境保全に関する協定書」、「水質汚濁防止法」並びに「茨城県条例」に基づき、平成27年4月1日から平成28年3月31日までの期間に日本原子力研究開発機構核燃料サイクル工学研究所から環境へ放出した放射性排水の放出管理結果をとりまとめたものである。再処理施設、プルトニウム燃料開発施設をはじめとする各施設からの放射性液体廃棄物は、濃度及び放出量ともに保安規定及び協定書等に定められた基準値を十分に下回った。, Based on the regulations (the safety regulation of Tokai reprocessing plant, the safety regulation of nuclear fuel material usage facilities, the radiation safety rule, the regulation about prevention from radiation hazards due to radioisotopes, which are related with the nuclear regulatory acts, the local agreement concerning with safety and environment conservation around nuclear facilities, the water pollution control law, and bylaw of Ibaraki prefecture), the effluent control of liquid waste discharged from the Nuclear Fuel Cycle Engineering Laboratories of Japan Atomic Energy Agency has been performed. This report describes the effluent control results of the liquid waste in the fiscal year 2015. In this period, the concentrations and the quantities of the radioactivity in liquid waste discharged from the reprocessing plant, the plutonium fuel fabrication facilities, and the other nuclear fuel material usage facilities were much lower than the limits authorized by the above regulations., 著者所属: 日本原子力研究開発機構(JAEA), JAEA-Review 2017-001

Published
2017

26. Mechanisms of neuronal death in synucleinopathy

Author

Takeda, Atsushi, Hasegawa, Takafumi, Matsuzaki-Kobayashi, Michiko, Sugeno, Naoto, Kikuchi, Akio, Itoyama, Yasuto, and Furukawa, Katsutoshi

Subjects
Research, Risk factors, Cell death -- Research -- Risk factors, Neurodegenerative diseases -- Research -- Risk factors, Nervous system -- Degeneration
Abstract

α-synuclein is a key molecule in the pathogenesis of synucleinopathy including Parkinson's disease and multiple system atrophy. In this mini-review, we mainly focus on recent data obtained from cellular models [...]

Published
2006

29. ESCRT-0 dysfunction compromises autophagic degradation of protein aggregates and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways

Author

Oshima, Ryuji, primary, Hasegawa, Takafumi, additional, Tamai, Keiichi, additional, Sugeno, Naoto, additional, Yoshida, Shun, additional, Kobayashi, Junpei, additional, Kikuchi, Akio, additional, Baba, Toru, additional, Futatsugi, Akira, additional, Sato, Ikuro, additional, Satoh, Kennichi, additional, Takeda, Atsushi, additional, Aoki, Masashi, additional, and Tanaka, Nobuyuki, additional

Published
2016
Full Text
View/download PDF

31. Brain Metabolic Changes of Cervical Dystonia with Spinocerebellar Ataxia Type 1 after Botulinum Toxin Therapy

Author

Kikuchi, Akio, primary, Takeda, Atsushi, additional, Sugeno, Naoto, additional, Miura, Emiko, additional, Kato, Kazuhiro, additional, Hasegawa, Takafumi, additional, Baba, Toru, additional, Konno, Masatoshi, additional, Oshima, Ryuji, additional, Watanuki, Shoichi, additional, Hiraoka, Kotaro, additional, Tashiro, Manabu, additional, and Aoki, Masashi, additional

Published
2016
Full Text
View/download PDF

32. 平成25年度核燃料サイクル工学研究所放出管理業務報告書(排水)

Author

渡辺 均, Watanabe, Hitoshi, 中野 政尚, Nakano, Masanao, 藤田 博喜, Fujita, Hiroki, 河野 恭彦, Kono, Takahiko, 井上 和美, Inoue, Kazumi, 吉井 秀樹, Yoshii, Hideki, 大谷 和義, Otani, Kazunori, 檜山 佳典, Hiyama, Yoshinori, 後藤 一郎, Goto, Ichiro, 木部 智, Kibe, Satoshi, 菊池 明夫, Kikuchi, Akio, 落合 一郎, Ochiai, Ichiro, 川崎 一男, Kawasaki, Ichio, 石山 道, Ishiyama, Toru, 西野 将平, Nishino, Shohei, 鈴木 高一, Suzuki, Takaichi, 織笠 正行, Orikasa, Masayuki, 渡辺 均, Watanabe, Hitoshi, 中野 政尚, Nakano, Masanao, 藤田 博喜, Fujita, Hiroki, 河野 恭彦, Kono, Takahiko, 井上 和美, Inoue, Kazumi, 吉井 秀樹, Yoshii, Hideki, 大谷 和義, Otani, Kazunori, 檜山 佳典, Hiyama, Yoshinori, 後藤 一郎, Goto, Ichiro, 木部 智, Kibe, Satoshi, 菊池 明夫, Kikuchi, Akio, 落合 一郎, Ochiai, Ichiro, 川崎 一男, Kawasaki, Ichio, 石山 道, Ishiyama, Toru, 西野 将平, Nishino, Shohei, 鈴木 高一, Suzuki, Takaichi, 織笠 正行, and Orikasa, Masayuki

Abstract

本報告書は、原子力規制関係法令を受けた「再処理施設保安規定」,「核燃料物質使用施設保安規定」,「放射線障害予防規程」,「放射線保安規則」及び「茨城県等との原子力施設周辺の安全確保及び環境保全に関する協定書」,「水質汚濁防止法」並びに「茨城県条例」に基づき,平成25年4月1日から平成26年3月31日までの期間に日本原子力研究開発機構核燃料サイクル工学研究所から環境へ放出した放射性排水の放出管理結果をとりまとめたものである。再処理施設, プルトニウム燃料開発施設をはじめとする各施設からの放射性液体廃棄物は、濃度及び放出量ともに保安規定及び協定書等に定められた基準値を十分に下回った。, Based on the regulations (the safety regulation of Tokai reprocessing plant, the safety regulation of nuclear fuel material usage facilities, the radiation safety rule, the regulation about prevention from radiation hazards due to radioisotopes, which are related with the nuclear regulatory acts, the local agreement concerning with safety and environment conservation around nuclear facilities, the water pollution control law, and bylaw of Ibaraki prefecture), the effluent control of liquid waste discharged from the Nuclear Fuel Cycle Engineering Laboratories of Japan Atomic Energy Agency has been performed. This report describes the effluent control results of the liquid waste in the fiscal year 2013. In this period, the concentrations and the quantities of the radioactivity in liquid waste discharged from the reprocessing plant, the plutonium fuel fabrication facilities, and the other nuclear fuel material usage facilities were much lower than the limits authorized by the above regulations., 著者所属: 日本原子力研究開発機構(JAEA), JAEA-Review 2014-040

Published
2015

35. Variants associated with Gaucher disease in multiple system atrophy

Author

Mitsui, Jun, primary, Matsukawa, Takashi, additional, Sasaki, Hidenao, additional, Yabe, Ichiro, additional, Matsushima, Masaaki, additional, Dürr, Alexandra, additional, Brice, Alexis, additional, Takashima, Hiroshi, additional, Kikuchi, Akio, additional, Aoki, Masashi, additional, Ishiura, Hiroyuki, additional, Yasuda, Tsutomu, additional, Date, Hidetoshi, additional, Ahsan, Budrul, additional, Iwata, Atsushi, additional, Goto, Jun, additional, Ichikawa, Yaeko, additional, Nakahara, Yasuo, additional, Momose, Yoshio, additional, Takahashi, Yuji, additional, Hara, Kenju, additional, Kakita, Akiyoshi, additional, Yamada, Mitsunori, additional, Takahashi, Hitoshi, additional, Onodera, Osamu, additional, Nishizawa, Masatoyo, additional, Watanabe, Hirohisa, additional, Ito, Mizuki, additional, Sobue, Gen, additional, Ishikawa, Kinya, additional, Mizusawa, Hidehiro, additional, Kanai, Kazuaki, additional, Hattori, Takamichi, additional, Kuwabara, Satoshi, additional, Arai, Kimihito, additional, Koyano, Shigeru, additional, Kuroiwa, Yoshiyuki, additional, Hasegawa, Kazuko, additional, Yuasa, Tatsuhiko, additional, Yasui, Kenichi, additional, Nakashima, Kenji, additional, Ito, Hijiri, additional, Izumi, Yuishin, additional, Kaji, Ryuji, additional, Kato, Takeo, additional, Kusunoki, Susumu, additional, Osaki, Yasushi, additional, Horiuchi, Masahiro, additional, Kondo, Tomoyoshi, additional, Murayama, Shigeo, additional, Hattori, Nobutaka, additional, Yamamoto, Mitsutoshi, additional, Murata, Miho, additional, Satake, Wataru, additional, Toda, Tatsushi, additional, Filla, Alessandro, additional, Klockgether, Thomas, additional, Wüllner, Ullrich, additional, Nicholson, Garth, additional, Gilman, Sid, additional, Tanner, Caroline M., additional, Kukull, Walter A., additional, Stern, Mathew B., additional, Lee, Virginia M.‐Y., additional, Trojanowski, John Q., additional, Masliah, Eliezer, additional, Low, Phillip A., additional, Sandroni, Paola, additional, Ozelius, Laurie J., additional, Foroud, Tatiana, additional, and Tsuji, Shoji, additional

Published
2015
Full Text
View/download PDF

37. 平成24年度核燃料サイクル工学研究所放出管理業務報告書(排水)

Author

住谷 秀一, Sumiya, Shuichi, 渡辺 均, Watanabe, Hitoshi, 宮河 直人, Miyagawa, Naoto, 中野 政尚, Nakano, Masanao, 藤田 博喜, Fujita, Hiroki, 河野 恭彦, Kono, Takahiko, 井上 和美, Inoue, Kazumi, 吉井 秀樹, Yoshii, Hideki, 大谷 和義, Otani, Kazunori, 檜山 佳典, Hiyama, Yoshinori, 後藤 一郎, Goto, Ichiro, 木部 智, Kibe, Satoshi, 菊池 明夫, Kikuchi, Akio, 山口 祐二, Yamaguchi, Yuji, 川崎 一男, Kawasaki, Ichio, 石山 道, Ishiyama, Toru, 西野 将平, Nishino, Shohei, 鈴木 高一, Suzuki, Takaichi, 織笠 正行, Orikasa, Masayuki, 住谷 秀一, Sumiya, Shuichi, 渡辺 均, Watanabe, Hitoshi, 宮河 直人, Miyagawa, Naoto, 中野 政尚, Nakano, Masanao, 藤田 博喜, Fujita, Hiroki, 河野 恭彦, Kono, Takahiko, 井上 和美, Inoue, Kazumi, 吉井 秀樹, Yoshii, Hideki, 大谷 和義, Otani, Kazunori, 檜山 佳典, Hiyama, Yoshinori, 後藤 一郎, Goto, Ichiro, 木部 智, Kibe, Satoshi, 菊池 明夫, Kikuchi, Akio, 山口 祐二, Yamaguchi, Yuji, 川崎 一男, Kawasaki, Ichio, 石山 道, Ishiyama, Toru, 西野 将平, Nishino, Shohei, 鈴木 高一, Suzuki, Takaichi, 織笠 正行, and Orikasa, Masayuki

Abstract

本報告書は、原子力規制関係法令を受けた「再処理施設保安規定」、「核燃料物質使用施設保安規定」、「放射線障害予防規程」、「放射線保安規則」及び「茨城県等との原子力施設周辺の安全確保及び環境保全に関する協定書」、「水質汚濁防止法」並びに「茨城県条例」に基づき、平成24年4月1日から平成25年3月31日までの期間に日本原子力研究開発機構核燃料サイクル工学研究所から環境へ放出した放射性排水の放出管理結果をとりまとめたものである。再処理施設、プルトニウム燃料開発施設をはじめとする各施設からの放射性液体廃棄物は、濃度及び放出量ともに保安規定及び協定書等に定められた基準値を十分に下回った。, Based on the regulations (the safety regulation of Tokai reprocessing plant, the safety regulation of nuclear fuel material usage facilities, the radiation safety rule, the regulation about prevention from radiation hazards due to radioisotopes, which are related with the nuclear regulatory acts, and the local agreement concerning with safety and environment conservation around nuclear facilities, the water pollution control law, and bylaw of Ibaraki prefecture), this report describes the effluent control results of liquid waste discharged from the JAEA's Nuclear Fuel Cycle Engineering Laboratories in the fiscal year 2012, from 1st April 2012 to 31st March 2013. In this period, the concentrations and the quantities of the radioactivity in liquid waste discharged from the reprocessing plant, the plutonium fuel fabrication facilities, and the other facilities were much lower than the authorized limits of the above regulations., 著者所属: 日本原子力研究開発機構(JAEA), JAEA-Review 2013-041

Published
2014

38. Lys-63-linked Ubiquitination by E3 Ubiquitin Ligase Nedd4-1 Facilitates Endosomal Sequestration of Internalized α-Synuclein

Author

Sugeno, Naoto, primary, Hasegawa, Takafumi, additional, Tanaka, Nobuyuki, additional, Fukuda, Mitsunori, additional, Wakabayashi, Koichi, additional, Oshima, Ryuji, additional, Konno, Masashi, additional, Miura, Emiko, additional, Kikuchi, Akio, additional, Baba, Toru, additional, Anan, Tadashi, additional, Nakao, Mitsuyoshi, additional, Geisler, Sven, additional, Aoki, Masashi, additional, and Takeda, Atsushi, additional

Published
2014
Full Text
View/download PDF

40. An Autopsy Case Involving a 12-year History of Amyotrophic Lateral Sclerosis with CIDP-like Polyneuropathy

Author

Akaishi, Tetsuya, primary, Tateyama, Maki, additional, Kato, Kazuhiro, additional, Miura, Emiko, additional, Izumi, Rumiko, additional, Endo, Kaoru, additional, Sugeno, Naoto, additional, Suzuki, Naoki, additional, Baba, Toru, additional, Misu, Tatsuro, additional, Kikuchi, Akio, additional, Hasegawa, Takafumi, additional, Konosu-Fukaya, Sachiko, additional, Fujishima, Fumiyoshi, additional, Suzuki, Hiroyoshi, additional, Nakashima, Ichiro, additional, and Aoki, Masashi, additional

Published
2014
Full Text
View/download PDF

42. Hypometabolism in the supplementary and anterior cingulate cortices is related to dysphagia in Parkinson's disease: a cross-sectional and 3-year longitudinal cohort study

Author

Kikuchi, Akio, primary, Baba, Toru, additional, Hasegawa, Takafumi, additional, Kobayashi, Michiko, additional, Sugeno, Naoto, additional, Konno, Masatoshi, additional, Miura, Emiko, additional, Hosokai, Yoshiyuki, additional, Ishioka, Toshiyuki, additional, Nishio, Yoshiyuki, additional, Hirayama, Kazumi, additional, Suzuki, Kyoko, additional, Aoki, Masashi, additional, Takahashi, Shoki, additional, Fukuda, Hiroshi, additional, Itoyama, Yasuto, additional, Mori, Etsuro, additional, and Takeda, Atsushi, additional

Published
2013
Full Text
View/download PDF

45. The AAA-ATPase VPS4 Regulates Extracellular Secretion and Lysosomal Targeting of α-Synuclein

Author

Hasegawa, Takafumi, primary, Konno, Masatoshi, additional, Baba, Toru, additional, Sugeno, Naoto, additional, Kikuchi, Akio, additional, Kobayashi, Michiko, additional, Miura, Emiko, additional, Tanaka, Nobuyuki, additional, Tamai, Keiichi, additional, Furukawa, Katsutoshi, additional, Arai, Hiroyuki, additional, Mori, Fumiaki, additional, Wakabayashi, Koichi, additional, Aoki, Masashi, additional, Itoyama, Yasuto, additional, and Takeda, Atsushi, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results